AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25172198 — intervention group
Group type: COMPARATOR
Intervention: Intensive blood pressure treatment (systolic blood pressure target <120 mmHg)
Number of subjects: 2856
Study 25172198 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of glycemia (hemoglobin A1c target 7.0% to 7.9%)
Number of subjects: 2856
Study 25172198 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus simvastatin
Number of subjects: 2856
Study 23732711 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of broad-spectrum sunscreen and 30 mg of β‐carotene
Number of subjects: 903
Study 23732711 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily use of sunscreen and placebo
Number of subjects: 903
Study 23732711 — intervention group
Group type: COMPARATOR
Intervention: Discretionary use of sunscreen and 30 mg of β‐carotene
Number of subjects: 903
Study 23732711 — intervention group
Group type: COMPARATOR
Intervention: Discretionary use of sunscreen and placebo
Number of subjects: 903
Study 23732711 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐Carotene supplementation
Number of subjects: 903
Study 20966372 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 507
Study 20966372 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 507
Study 18537221 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (120 mg daily)
Number of subjects: 176
Study 18537221 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 176
Study 16600225 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 228
Study 16600225 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive sham acupuncture (control)
Number of subjects: 228
Study 14732982 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized dentin matrix (DDM)
Number of subjects: 57
Study 14732982 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide
Number of subjects: 57
Study 10750855 — intervention group
Group type: EXPERIMENTAL
Intervention: Body lotion (specific product not named), applied 2 times a day for 14 days
Number of subjects: 0
Study 10750855 — intervention group
Group type: EXPERIMENTAL
Intervention: Body lotion (specific product not named), applied to SLS-damaged skin
Number of subjects: 0
Study 8960590 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced prominent U wave
Number of subjects: 0
Study 8960590 — intervention group
Group type: EXPERIMENTAL
Intervention: U-wave increase with or without ST-segment depression
Number of subjects: 0
Study 8960590 — intervention group
Group type: EXPERIMENTAL
Intervention: Prominent U wave
Number of subjects: 0
Study 1541031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid intervention
Number of subjects: 6
Study 3887075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative pancreatic duct occlusion (PDO) during partial duodenopancreatectomy
Number of subjects: 0
Study 3887075 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic pancreatic duct occlusion (PDO)
Number of subjects: 0
Study 3887075 — intervention group
Group type: COMPARATOR
Intervention: Partial duodenopancreatectomy
Number of subjects: 0
Study 31623511 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance-based coping (avoid thinking about HIV)
Number of subjects: 162
Study 28090806 — intervention group
Group type: EXPERIMENTAL
Intervention: actual deep TMS (dTMS)
Number of subjects: 26
Study 28090806 — intervention group
Group type: COMPARATOR
Intervention: sham
Number of subjects: 26
Study 27923947 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin plus Piperaquine (DHAp)
Number of subjects: 0
Study 27923947 — intervention group
Group type: COMPARATOR
Intervention: No mass treatment (Control)
Number of subjects: 0
Study 24439998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of 300 mg bupivacaine
Number of subjects: 100
Study 24439998 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 100
Study 21904819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine inhalers (NI; 4 mg deliverable)
Number of subjects: 28
Study 21904819 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalers
Number of subjects: 28
Study 20860820 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for GPs in risk communication and shared decision-making
Number of subjects: 560
Study 20860820 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 560
Study 17440782 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (group A)
Number of subjects: 22
Study 17440782 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B)
Number of subjects: 22
Study 12634227 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical nurse specialist care
Number of subjects: 210
Study 12634227 — intervention group
Group type: COMPARATOR
Intervention: Inpatient team care
Number of subjects: 210
Study 12634227 — intervention group
Group type: COMPARATOR
Intervention: Day patient team care
Number of subjects: 210
Study 10869917 — intervention group
Group type: EXPERIMENTAL
Intervention: 56% of xenon (Group X)
Number of subjects: 39
Study 10869917 — intervention group
Group type: COMPARATOR
Intervention: 0.94% of isoflurane (Group I)
Number of subjects: 39
Study 10869917 — intervention group
Group type: COMPARATOR
Intervention: 70% of nitrous oxide and 0.15% of isoflurane (Group N)
Number of subjects: 39
Study 9347378 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (mean dose 675 mg/day)
Number of subjects: 315
Study 9347378 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (high dose 220 mg/day)
Number of subjects: 315
Study 9347378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 9347378 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 315
Study 9347378 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 315
Study 1609753 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-enriched semielemental formulation
Number of subjects: 19
Study 1609753 — intervention group
Group type: COMPARATOR
Intervention: Matched standard semielemental formulation
Number of subjects: 19
Study 4060026 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based nutrition education programme in addition to routine medical care
Number of subjects: 63
Study 4060026 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care only (Control)
Number of subjects: 63
Study 4060026 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnourished children (matched for age and sex with a normal group)
Number of subjects: 63
Study 31818329 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐choledochoduodenostomy using a LAMS
Number of subjects: 130
Study 31818329 — intervention group
Group type: COMPARATOR
Intervention: ERCP with traditional metal stent insertion
Number of subjects: 130
Study 29055449 — intervention group
Group type: EXPERIMENTAL
Intervention: APP-based home therapy program for 3 months
Number of subjects: 20
Study 29055449 — intervention group
Group type: COMPARATOR
Intervention: Paper-based home therapy program for 3 months
Number of subjects: 20
Study 26369654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 15 mg with 4% alcohol
Number of subjects: 40
Study 26369654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 15 mg with 20% alcohol
Number of subjects: 40
Study 26369654 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocodone ER 15 mg with 40% alcohol
Number of subjects: 40
Study 26369654 — intervention group
Group type: COMPARATOR
Intervention: Hydrocodone ER 15 mg with water
Number of subjects: 40
Study 23983697 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intranasal steroid
Number of subjects: 200
Study 23983697 — intervention group
Group type: COMPARATOR
Intervention: Postoperative intranasal saline spray
Number of subjects: 200
Study 21220471 — intervention group
Group type: EXPERIMENTAL
Intervention: PF299804 (45 mg/d) administered once daily continuously (schedule A) and intermittently (schedule B)
Number of subjects: 121
Study 21220471 — intervention group
Group type: EXPERIMENTAL
Intervention: PF299804 (45 mg/d) administered once daily continuously (schedule A)
Number of subjects: 121
Study 21220471 — intervention group
Group type: EXPERIMENTAL
Intervention: PF299804 (45 mg/d) administered intermittently (schedule B)
Number of subjects: 121
Study 21220471 — intervention group
Group type: EXPERIMENTAL
Intervention: PF299804
Number of subjects: 121
Study 19728200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ammonium chloride (to induce acidosis)
Number of subjects: 12
Study 19728200 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 12
Study 16963172 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50mg
Number of subjects: 50
Study 16963172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15213580 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate combined with multimodal psychosocial treatment (parent training, counseling, academic assistance, psychotherapy, social skills training)
Number of subjects: 103
Study 15213580 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate alone
Number of subjects: 103
Study 15213580 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate plus attention control treatment (excluding specific aspects of psychosocial intervention)
Number of subjects: 103
Study 10839593 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B oral suspension (ABOS), 100 mg/ml, 5 ml swish and swallow, four times daily for 14 days
Number of subjects: 54
Study 10839593 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B oral suspension (ABOS) maintenance therapy, twice daily for up to 6 months
Number of subjects: 54
Study 10839593 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B oral suspension (ABOS)
Number of subjects: 54
Study 9387720 — intervention group
Group type: EXPERIMENTAL
Intervention: Piweiping capsule (PWPC)
Number of subjects: 143
Study 9387720 — intervention group
Group type: COMPARATOR
Intervention: Sanjiu Weitai (SJWT)
Number of subjects: 143
Study 1348797 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin per day
Number of subjects: 184
Study 1348797 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin twice daily
Number of subjects: 184
Study 1348797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 4067168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually active older person
Number of subjects: 140
Study 4067168 — intervention group
Group type: COMPARATOR
Intervention: Non-sexually active older person
Number of subjects: 140
Study 31215509 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media platform-based HIV risk prediction tool
Number of subjects: 0
Study 31215509 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram and WeChat-based HIV incidence risk assessment tools
Number of subjects: 0
Study 28801083 — intervention group
Group type: EXPERIMENTAL
Intervention: Peyton's Four-Step Approach (n = 30)
Number of subjects: 60
Study 28801083 — intervention group
Group type: COMPARATOR
Intervention: Halsted's method (n = 30)
Number of subjects: 60
Study 27402726 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 50 mg
Number of subjects: 0
Study 27402726 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 10 mg
Number of subjects: 0
Study 27402726 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 50 mg with low-fat meal
Number of subjects: 0
Study 27402726 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 50 mg with high-fat meal
Number of subjects: 0
Study 27402726 — intervention group
Group type: EXPERIMENTAL
Intervention: Population PK modeling
Number of subjects: 0
Study 24240353 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5%
Number of subjects: 241
Study 24240353 — intervention group
Group type: COMPARATOR
Intervention: Rewetting solution (control)
Number of subjects: 241
Study 23243238 — intervention group
Group type: EXPERIMENTAL
Intervention: FG (fermented Ginkgo biloba leaves)
Number of subjects: 180
Study 23243238 — intervention group
Group type: COMPARATOR
Intervention: NF (nonfermented Ginkgo biloba leaves)
Number of subjects: 180
Study 23243238 — intervention group
Group type: COMPARATOR
Intervention: Control (basal diet)
Number of subjects: 180
Study 20008428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Track conduct disorder prevention program
Number of subjects: 891
Study 20008428 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 891
Study 18421269 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg/day calcium supplement
Number of subjects: 24
Study 18421269 — intervention group
Group type: EXPERIMENTAL
Intervention: three servings of dairy products/day to achieve an additional 900 mg/day
Number of subjects: 24
Study 18421269 — intervention group
Group type: COMPARATOR
Intervention: placebo (<800 mg/day calcium intake)
Number of subjects: 24
Study 16438767 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 20
Study 16438767 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride solution
Number of subjects: 20
Study 12905057 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of mortality model developed from 827 patients.
Number of subjects: 1242
Study 12905057 — intervention group
Group type: EXPERIMENTAL
Intervention: Probability of mortality model validated on 415 patients.
Number of subjects: 1242
Study 11111294 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow infusion of Levovist at 1 ml/min (average dose 4.2 g)
Number of subjects: 12
Study 11111294 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast infusion of Levovist at 3 ml/min (average dose 7 g)
Number of subjects: 12
Study 11111294 — intervention group
Group type: COMPARATOR
Intervention: Bolus injections of Levovist (1 or 2 injections of 4 g each)
Number of subjects: 12
Study 8856832 — intervention group
Group type: EXPERIMENTAL
Intervention: Low nicotine training dose (10 micrograms/kg)
Number of subjects: 33
Study 8856832 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine training dose (30 micrograms/kg)
Number of subjects: 33
Study 8856832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 micrograms/kg)
Number of subjects: 33
Study 1733360 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (3 x 100 micrograms subcutaneously for 7 days)
Number of subjects: 246
Study 1733360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously for 7 days)
Number of subjects: 246
Study 1733360 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide in high-risk stratum
Number of subjects: 246
Study 1733360 — intervention group
Group type: COMPARATOR
Intervention: Placebo in high-risk stratum
Number of subjects: 246
Study 1733360 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide in low-risk stratum
Number of subjects: 246
Study 1733360 — intervention group
Group type: COMPARATOR
Intervention: Placebo in low-risk stratum
Number of subjects: 246
Study 1733360 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 246
Study 1733360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 31792864 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for social needs and referral to trained volunteer advocates
Number of subjects: 102
Study 31792864 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistance with filling out forms and calling community resources
Number of subjects: 102
Study 31792864 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction with advocates
Number of subjects: 102
Study 30445386 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-night wake therapy (EWT: sleep 3:00-7:00 am)
Number of subjects: 50
Study 30445386 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-night wake therapy (LWT: sleep 9:00 pm-01:00 am)
Number of subjects: 50
Study 27864725 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscope-assisted surgery
Number of subjects: 46
Study 27864725 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 46
Study 26103995 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track intervention (Hospital2Home)
Number of subjects: 53
Study 26103995 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 23497326 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving On self-management program
Number of subjects: 250
Study 23497326 — intervention group
Group type: COMPARATOR
Intervention: Light physical activity (control)
Number of subjects: 250
Study 21239096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 183
Study 21239096 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 183
Study 20882729 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 138
Study 20882729 — intervention group
Group type: COMPARATOR
Intervention: Health education (control)
Number of subjects: 138
Study 16996315 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg/day started 1 day before surgery and continued for 14 days
Number of subjects: 0
Study 16996315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16387120 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial liver support system (ALSS) treatment for 1 to 8 sessions
Number of subjects: 338
Study 16387120 — intervention group
Group type: COMPARATOR
Intervention: Conventional medications
Number of subjects: 338
Study 12549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions for antisocial behavior
Number of subjects: 0
Study 12549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediational analyses
Number of subjects: 0
Study 12549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderator analyses
Number of subjects: 0
Study 12549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Change processes assessment
Number of subjects: 0
Study 12549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Constructive and dismantling designs
Number of subjects: 0
Study 12549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-sensitive nature of change mechanisms
Number of subjects: 0
Study 12549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Expansion of nomological net
Number of subjects: 0
Study 12549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Direction of effects questions
Number of subjects: 0
Study 12549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary analyses of RCTs
Number of subjects: 0
Study 12549700 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalizability of effects
Number of subjects: 0
Study 9587720 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing intracuff pressure to the minimum required for an effective seal
Number of subjects: 839
Study 7888970 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholscreen Program (five-session intervention by the GP)
Number of subjects: 378
Study 7888970 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (single session of 5 minutes' advice by the GP plus a self-help manual)
Number of subjects: 378
Study 7888970 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-related assessment (but no intervention)
Number of subjects: 378
Study 7888970 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention nor assessment
Number of subjects: 378
Study 2230065 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg des-enkephalin-gamma-endorphin (DE gamma E) daily
Number of subjects: 93
Study 2230065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 98822 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate 2% nasal solution
Number of subjects: 0
Study 98822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30762290 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 471
Study 30762290 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 471
Study 30762290 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 471
Study 28003352 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV at 5 months (arm A)
Number of subjects: 900
Study 28003352 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV at enrollment (arm B)
Number of subjects: 900
Study 28003352 — intervention group
Group type: COMPARATOR
Intervention: No vaccine (arm C)
Number of subjects: 900
Study 26448633 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin (3500 IU subcutaneous for 7 days)
Number of subjects: 774
Study 26448633 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (standard rehydration and advice on ambulation)
Number of subjects: 774
Study 22669549 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted TKA
Number of subjects: 100
Study 22669549 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 100
Study 22669549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 21784326 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic ear drops plus standard therapy
Number of subjects: 119
Study 21784326 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 119
Study 19435587 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 81
Study 19435587 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 81
Study 16738022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ego-threatened participants
Number of subjects: 0
Study 16738022 — intervention group
Group type: COMPARATOR
Intervention: Nonthreatened participants
Number of subjects: 0
Study 15112182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) vaccination with 5 microg of recombinant HBV vaccine every week for a total of 10 doses
Number of subjects: 60
Study 15112182 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) vaccination with 20 microg at 0, 1, and 6 months
Number of subjects: 60
Study 10645749 — intervention group
Group type: EXPERIMENTAL
Intervention: High-affiliation conversations in female dyads
Number of subjects: 104
Study 10645749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutual-participation goals in female dyads
Number of subjects: 104